
Collaboration in Biopharma
pharmafile | November 22, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, drugs, pharma, pharmaceutical
Dear Colleague,
Biopharmaceutical companies are increasingly partnering with a diverse set of health care stakeholders to address scientific and technological challenges – but what makes the most effective collaborative process? We invite you to participate in this short industry-wide survey which seeks to analyse the quality of collaborative processes in the biopharmaceutical industry.
A £5 donation will be made to The Haller Foundation* for each completed survey (up to a maximum of £1,000).
Thank you for your time and consideration.
On behalf of CHASE
* Haller is a UK registered charity set up to help rural communities in Africa to become self-sufficient in a sustainable manner. Haller provides poor and rural communities with the means and knowledge to have sustainable water and food security, access to basic healthcare and education and nano-financing to kick start income generating businesses.
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …






